Dojin Group Co., Ltd. entered into a share transfer agreement to acquire Advanced Cell Technology and Engineering Ltd. from Gene Techno Science Co.,Ltd. (TSE:4584) for ¥0 on July 10, 2020. After completion, Advanced Cell Technology and Engineering will become a subsidiary of Dojin Group. With the transfer of shares, Remcare Co., Ltd., a wholly owned subsidiary of Advanced Cell Technology will also become Dojin Group's subsidiary. As of November 12, 2020, Dojin Group Co., Ltd. has been replaced as buyer with Reverse Co., Ltd.. Post completion, Advanced Cell Technology and Engineering Ltd. will become wholly owned subsidiary of Reverse Co., Ltd. As at March 31, 2020, Advanced Cell Technology and Engineering had total assets of ¥84.6 million and net assets of ¥43.7 million . For the year ended March 31, 2020, Advanced Cell Technology and Engineering had revenues of ¥83.2 million, operating loss of ¥226.5 million and net loss of ¥50.8 million. The Board of Directors of Dojin Group and Gene Techno Science at the meeting held on July 10, 2020 resolved the transaction. The transaction is expected to complete on September 30, 2020. As of September 30, 2020, execution date of the share transfer has been postponed to December 31, 2020.